The Relationship of Plasma Aβ Levels to Dementia in Aging Individuals With Down Syndrome
Authors:
- 1 October 2009
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Alzheimer Disease & Associated Disorders
- Vol. 23 (4) , 315-318
Abstract
To study the relationship between plasma levels of amyloid β (Aβ) peptides and dementia in aging individuals with Down syndrome, we investigated the relationship among plasma Aβ, apolipoprotein E genotype and cognitive and clinical factors using baseline specimens form participants in an ongoing clinical trial in individuals with Down syndrome 50 years of age and older. Because of substantial skew in the distribution of peptide levels, analyses used log transformations of the data. The ratio of Aβ42 to Aβ40 was associated with the presence of dementia (P=0.003, df=196, F=9.37); this association persisted after adjustment for age, sex level of mental retardation, and apolipoprotein E genotype. Consistent with recent reports regarding the effect of presenilin mutations on peptide generation, our finding supports the theory that the ratio of Aβ42 to Aβ40 rather than absolute levels of the peptides is important to the pathophysiology of Alzheimer's disease in genetically susceptible populations.Keywords
This publication has 25 references indexed in Scilit:
- Elevated Plasma β-Amyloid Peptide Aβ42 Levels, Incident Dementia, and Mortality in Down SyndromeArchives of Neurology, 2007
- Plasma levels of beta-amyloid (1–42) in Alzheimer's disease and mild cognitive impairmentNeurobiology of Aging, 2006
- Presenilin clinical mutations can affect γ‐secretase activity by different mechanismsJournal of Neurochemistry, 2006
- Assessment of Aging Individuals with Down Syndrome in Clinical Trials: Results of Baseline MeasuresJournal of Policy and Practice in Intellectual Disabilities, 2005
- Design and Implementation of a Multicenter Trial of Vitamin E in Aging Individuals with Down SyndromeJournal of Policy and Practice in Intellectual Disabilities, 2005
- Plasma amyloid β protein 1–42 levels are increased in old Down Syndrome but not in young Down SyndromeNeuroscience Letters, 2003
- Standardization of measurement of β-amyloid(1-42)in cerebrospinal fluid and plasmaAmyloid, 2000
- Molecular mapping of alzheimer‐type dementia in Down's syndromeAnnals of Neurology, 1998
- Amyloid β Protein in Plasma as a Diagnostic Marker for Alzheimer’s DiseaseNeurobiology of Aging, 1998
- Increased plasma amyloid β protein 1–42 levels in Down syndromeNeuroscience Letters, 1998